1 citations
,
August 2021 in “Journal of Investigative Dermatology” ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.
18 citations
,
January 2021 in “Theranostics” The targeted nanohybrids effectively reduced psoriasis symptoms and improved skin health.
2 citations
,
January 2012 in “Hair therapy & transplantation” DDAIP-HCl significantly increases minoxidil absorption into the skin.
February 2017 in “대한피부과학회지” Combining low-dose dutasteride with finasteride improved a man's hair loss.
January 2024 in “Expert Opinion on Pharmacotherapy” Low-dose oral minoxidil is effective and safe for treating hair loss in men and women.
December 2022 in “Clinical and experimental dermatology and therapies” Adding the topical gel improved hair growth more than using minoxidil or finasteride alone.
5 citations
,
January 2015 in “Molecular Genetics and Metabolism” 6 citations
,
October 2024 in “Frontiers in Bioengineering and Biotechnology” A special hydrogel helps stem cells heal wounds better by boosting growth factors.
June 2026 in “Precision medicine and engineering.” The hydrogel dressing RD@PVA helps heal diabetic wounds by reducing stress and improving blood vessel growth.
December 2022 in “Small methods” A new hair loss treatment using dissolving microneedles was found to speed up hair growth and was more effective than daily use of common hair growth drugs.
January 2023 in “Reactions Weekly” March 2023 in “Reactions Weekly” January 2023 in “Reactions Weekly” January 2023 in “Reactions Weekly”
October 2024 in “International Journal of Research in Medical Sciences” The SULT1A1 enzyme booster improves minoxidil effectiveness in treating hair loss, especially in females.
1 citations
,
August 2018 in “Journal of The American Academy of Dermatology” Dutasteride and minoxidil mesotherapy effectively treats hair loss with minimal side effects.
June 2025 in “Experimental and Сlinical Urology” Predstanormix Duo is a safe and effective new drug for treating urinary symptoms from BPH.
January 2025 in “Journal of Materials Chemistry B” A new treatment using special microneedles and a nitric oxide-releasing drug could improve hair growth and be more convenient for people with hair loss.
12 citations
,
February 2010 in “Tetrahedron Letters” New minoxidil compounds with better water solubility were made, but their full effects and safety need more research.
3 citations
,
November 2005 in “Dermatologic Surgery” Aminoguanidine increases a specific growth signal in stored hair grafts, which may help them survive better after being transplanted.
2 citations
,
January 2001 in “Biomedical Research” Trichohyalin and peptidylarginine deiminase type III are found together in rat hair follicles, with trichohyalin being modified after expression.
43 citations
,
July 2018 in “Journal of The European Academy of Dermatology and Venereology” Finasteride and minoxidil mix works better for hair growth than minoxidil alone, with similar safety.
December 2023 in “Journal of Medicinal Chemistry” A new topical treatment for hair loss shows strong hair growth effects with low toxicity.
July 2024 in “Journal of Investigative Dermatology” ATR04-484 ointment shows promise for treating skin issues from cancer therapies.
Ganoderma Lucidum extract and ganoderic acid A can help prevent hair loss.
February 2023 in “Materials today bio” The treatment effectively promotes hair regrowth in androgenetic alopecia without causing skin irritation.
January 2016 in “Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature” A substance called prostaglandin D2 is found more in bald scalps and it stops hair from growing. Blocking its receptor could potentially treat hair loss.
November 2025 in “OPAL (Open@LaTrobe) (La Trobe University)” DAB labeling effectively identifies collagen type III and PDGFR in horse skin, but may show false positives.
February 2020 in “Benha Journal of Applied Sciences” Higher Galectin-3 levels are linked to insulin resistance and may predict androgenetic alopecia severity.
45 citations
,
July 2025 in “Journal of Medicinal Chemistry” Vepdegestrant may become the first FDA-approved PROTAC degrader, marking a new era in drug development.